BioCentury
ARTICLE | Clinical News

IV solithromycin: Phase III data

October 26, 2015 7:00 AM UTC

The EMA-defined primary endpoint was non-inferiority in the ITT and CE populations of patients with CABP in PORT pneumonia severity risk classes III and IV at the short-term follow-up visit. Solithrom...